CRISPR Therapeutics AG

By person

29 insiders · 552 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Bolzon Bradley J PhD

Director

$2.25M (4)

$121.48M (128)

−$119.23M

148,831

0.1539%

$8.28M

−73.2%

Novak Rodger

President

—

$72.16M (54)

−$72.16M

573,007

0.5926%

$31.87M

−52.8%

Kulkarni Samarth

Chief Executive Officer

—

$65.03M (107) scheduled

−$65.03M

255,501

0.2642%

$14.21M

+91.4%

George Simeon

Director

$52.43M (4)

—

+$52.43M

1,730,179

1.79%

$96.23M

—

EMSTER KURT VON

Director

$2.28M (2)

$52.74M (46)

−$50.46M

1,164,268

1.20%

$64.76M

+39,772%

Klein Lawrence Otto

CBO & COO

—

$26.01M (27) scheduled

−$26.01M

26,797

0.0277%

$1.49M

—

Woiwode Thomas

Director

$2.25M (4)

$27.77M (34)

−$25.52M

645,643

0.6677%

$35.91M

—

BAYER AKTIENGESELLSCHAFT

10% owner

$12.00M (1)

—

+$12.00M

5,632,802

5.83%

$313.30M

+10.3%

CELGENE CORP /DE/ entity

10% owner

$11.20M (1)

$21.12M (21)

−$9.92M

9,007,999

9.32%

$501.02M

+70.4%

KASINGER JAMES R.

General Counsel and Secretary

—

$7.71M (19) scheduled

−$7.71M

94,308

0.0975%

$5.25M

+3,604%

TOMSICEK MICHAEL JOHN

Chief Financial Officer

—

$5.61M (7) scheduled

−$5.61M

1,891

0.0020%

$105.18K

+361.2%

Prasad Raju

Chief Financial Officer

—

$5.60M (13) scheduled

−$5.60M

14,815

0.0153%

$824.01K

—

Versant Venture Capital IV, L.P. entity

10% owner

—

$5.17M (4)

−$5.17M

117,173

0.1212%

$6.52M

−95.9%

Dylan-Hyde Tyler

Chief Legal Officer

—

$5.01M (25) scheduled

−$5.01M

25,204

0.0261%

$1.40M

−87.7%

Ho Tony W

Executive VP, Head of R&D

—

$4.52M (13) scheduled

−$4.52M

52,364

0.0542%

$2.91M

—

Vertex Pharmaceuticals (Europe) Ltd entity

10% owner

$3.19M (6)

—

+$3.19M

5,380,940

5.56%

$299.29M

+2.5%

CAGNONI PABLO J

Director

—

$1.73M (5) scheduled

−$1.73M

0.0000%

$0.00

—

Versant Venture Capital V, L.P. entity

10% owner

—

$1.16M (4)

−$1.16M

115,645

0.1196%

$6.43M

−16.5%

Treco Douglas A

Director

$1.14M (1)

—

+$1.14M

22,000

0.0228%

$1.22M

+1,000%

GSK plc entity

10% owner

$931.00K (1)

—

+$931.00K

3,220,627

3.33%

$179.13M

—

Patel Naimish

Chief Medical Officer

$49.70K (1)

$503.91K (3)

−$454.21K

19,357

0.0200%

$1.08M

+3,170%

Bruno Julianne

Chief Operating Officer

—

$336.10K (5)

−$336.10K

10,544

0.0109%

$586.46K

+238.9%

Greene John

Director

$313.95K (1)

—

+$313.95K

7,000

0.0072%

$389.34K

—

Lundberg Sven Ante

Chief Scientific Officer

$5.60K (1)

—

+$5.60K

1,010,834

1.05%

$56.22M

+5.8%

Hadley Harbor Master Investors (Cayman) L.P.

10% owner

—

744,380

0.7698%

$41.40M

—

COLES N ANTHONY

Director

—

70,000

0.0724%

$3.89M

—

Smith Brendan

Chief Financial Officer

—

5,072

0.0052%

$282.10K

—

Morrow Phuong Khanh

Chief Medical Officer

—

4,411

0.0046%

$245.34K

—

Behbahani Ali

Director

—

270

0.0003%

$15.02K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Treco Douglas A

6 Aug 2025

Director

Buy

20,000

$57.03

$1.14M

George Simeon

16 Jul 2025

Director

Buy indirect

960,983

$52.03

$50.00M

George Simeon

16 Jul 2025

Director

Buy indirect

22,319

$52.03

$1.16M

George Simeon

16 Jul 2025

Director

Buy indirect

6,510

$52.03

$338.72K

Patel Naimish

3 Apr 2025

Chief Medical Officer

Buy

1,508

$32.96

$49.70K

Greene John

26 Feb 2025

Director

Buy

7,000

$44.85

$313.95K

Showing 250 of 552 transactions. The figures above use every one of them.

By person

Individual transactions

What was left out